COMPANY

Sentrimed

HQ: Mullica Hill, NJ source · sentrimed.com ↗ · Mid-Atlantic

Keywords: oncology head and neck cancer

Location: Mullica Hill, NJ · source · Oct 15, 2026

Profile checked Oct 10, 2026

NIH awards 3

Annual award amounts. Total $604K.

Nov 29, 2023 NIH award 6R41CA268160-03 FY2023: $247,657 awarded for that fiscal year; activity R41 (STTR); PI GOLDBERG, GARY S; recipient as written: SENTRIMED, INC., MULLICA HILL, NJ. Targeting OSCC cells with a lozenge to treat source ↗
Jul 14, 2023 NIH award 5R41CA268160-02 FY2023: $33,576 awarded for that fiscal year; activity R41 (STTR); PI GOLDBERG, GARY S; recipient as written: SENTRIMED, INC., MULLICA HILL, NJ. Targeting OSCC cells with a lozenge to treat source ↗
Jul 6, 2022 NIH award 1R41CA268160-01A1 FY2022: $322,833 awarded for that fiscal year; activity R41 (STTR); PI GOLDBERG, GARY S; recipient as written: SENTRIMED, INC., MULLICA HILL, NJ. Targeting OSCC cells with a lozenge to tre source ↗

SEC Form D raise Raised $250K in debt securities (Form D filed May 13, 2026). SEC Form D 0002014313-26-000002 (May 13, 2026)
Evidence (1 event)
- May 13, 2026 · SEC Form D 0002014313-26-000002
  Name of Issuer: Sentrimed, Inc.; CIK: 2014313; Address: Mullica Hill, NJ; Submission type: D; Filing date: 2026-05-13; Industry Group: Biotechnology; Date of First Sale: 2026-05-08; Types of Securities Offered: Debt, Security to be acquired; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 250000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals